NCT06188507View on ClinicalTrials.gov

A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy Participants

PHASE1SuspendedINTERVENTIONAL

Enrollment

65

Participants

Timeline

Start Date

January 12, 2024

Primary Completion Date

July 14, 2026

Study Completion Date

July 14, 2026

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG

GSK4347859

GSK4347859 will be administered

DRUG

Placebo

Placebo will be administered

Trial Locations (2)

CB2 2GG

GSK Investigational Site, Cambridge

NG11 6JS

GSK Investigational Site, Nottingham

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY